ALSO NOTED: FDA studies blindness; Roche gets OK for HIV drug; FDA approves Zemplar; and much more...

> The FDA is examining a handful of cases in which men taking Viagra have gone blind. The agency says that there is currently no known link, but that it will investigate. Story

> Roche has received European marketing approval for 500 mg formulation of the HIV drug Invirase. Story

> The FDA has approved Abbott's Zemplar (paricalcitol) for the prevention and treatment of secondary hyperparathyroidism. Release

> The FDA has approved Novartis Pharmaceuticals' extended release form of Focalin for ADHD, which is licensed from Celgene. Story

> Ariad has begun its first clinical trial of oral AP23573 in patients with relapsed or refractory cancers. Release

> NovaDel Pharma of Flemington, New Jersey, raised $7 million in a private placement. Release

> Santarus has filed an NDA for Zegerid chewable tablets. Release

> King Pharmaceuticals and Astellas have filed suit against several generic drug makers following their ANDA for Adenoscan, a pharmacologic stress agent. Release

And Finally... A group of scientists is challenging new research claiming that people who are slightly overweight live longer. Story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.